TrialThe lancet. Diabetes & endocrinology2024

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.